Robert Borzilleri

List of Publications by Year
in descending order

27 papers	2,790 citations	361045 20 h-index	525886 27 g-index
27 all docs	27 docs citations	27 times ranked	3899 citing authors

#	Article	IF	Citations
1	Discovery ofN-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 627 Td (Activity in Preclinical Assays. Journal of Medicinal Chemistry, 2004, 47, 6658-6661.	2.9	1,196
2	Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily. Journal of Medicinal Chemistry, 2009, 52, 1251-1254.	2.9	265
3	Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3249-3254.	3.3	157
4	Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (methy Inhibitor. Journal of Medicinal Chemistry, 2006, 49, 2143-2146.	2.9	136
5	Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl 2- A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215). Journal of Medicinal Chemistry, 2008, 51, 1976-1980.	2.9	135
6	Discovery of Pyrrolopyridineâ”Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 5330-5341.	2.9	115
7	Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemotherapy and Pharmacology, 2008, 63, 157-166.	1.1	103
8	Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template. Journal of Medicinal Chemistry, 2004, 47, 4054-4059.	2.9	92
9	Synthesis and Biological Activity of Novel Epothilone Aziridines. Organic Letters, 2001, 3, 2693-2696.	2.4	73
10	Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 3991-4008.	2.9	65
11	Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3224-3229.	1.0	62
12	Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1945-1951.	1.0	56
13	Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3937-3942.	1.0	49
14	Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2095-2100.	1.0	46
15	Discovery and Evaluation ofN-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Endothelial Growth Factor Receptor-2. Journal of Medicinal Chemistry, 2006, 49, 3766-3769.	2.9	40
16	Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3946-3950.	1.0	30
17	Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Experimental Cell Research, 2015, 332, 267-277.	1.2	28
18	Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1354-1358.	1.0	27

#	Article	IF	Citations
19	Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity. Chemical Research in Toxicology, 2012, 25, 556-571.	1.7	23
20	Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3951-3956.	1.0	22
21	Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Analytical Biochemistry, 2009, 392, 59-69.	1.1	19
22	Design, synthesis and structureâ€“activity relationships of novel biarylamine-based Met kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2998-3002.	1.0	16
23	Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Medicinal Chemistry Letters, 2021, 12, 288-294.	1.3	15
24	Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2021, 12, 494-501.	1.3	10
25	TGFÎ²2 and TGFÎ²3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells. IScience, 2021, 24, 102133.	1.9	4
26	An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. Drug Discovery Today, 2021, 26, 1115-1125.	3.2	3
27	Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1143-1150.	1.3	3